OPEN END TURBO OPTIONSSCHEIN LONG - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 03:00:06 2024-07-11 am EDT | ||
| 15.63 EUR | +0.32% |
|
| Current month | +7.60% | ||
| 1 month | +1.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 15.63 | +0.32% |
| 24-07-10 | 15.58 | +2.30% |
| 24-07-09 | 15.23 | +2.56% |
| 24-07-08 | 14.85 | +4.36% |
| 24-07-05 | 14.23 | +2.52% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 03:00 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GX9B68 |
| ISIN | DE000GX9B682 |
| Date issued | 2022-09-06 |
| Strike | 322.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.63 € |
|---|---|
| Lowest since issue | 0.219 € |
| Spread | 0.2 € |
| Spread % | 1.25% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
491.6
USD
Average target price
471.3
USD
Spread / Average Target
-4.13%
- Stock Market
- Certificates
- Certificat
